Sermorelin.
Sermorelin is a synthetic 29-amino-acid peptide corresponding to the N-terminal 1-29 fragment of human growth hormone-releasing hormone (GHRH), the hypothalamic hormone that signals the pituitary to release growth hormone (GH).
Sermorelin is a synthetic 29-amino-acid peptide corresponding to the N-terminal 1-29 fragment of human growth hormone-releasing hormone (GHRH), the hypothalamic hormone that signals the pituitary to release growth hormone (GH). Sermorelin is research / preclinical, and PepCue grades its published evidence C tier (58/100). This is a research reference, not medical or dosing advice.
What it is
Sermorelin is a synthetic 29-amino-acid peptide corresponding to the N-terminal 1-29 fragment of human growth hormone-releasing hormone (GHRH), the hypothalamic hormone that signals the pituitary to release growth hormone (GH). This 1-29 fragment is the shortest portion of GHRH that retains full biological activity, so sermorelin behaves as a functional GHRH analog (a "secretagogue") rather than as growth hormone itself. It was marketed under the brand names Geref and Geref Diagnostic.
How it works
Sermorelin binds the GHRH receptor on pituitary somatotroph cells, a Gs-protein-coupled receptor, raising intracellular cAMP and stimulating synthesis and pulsatile secretion of endogenous growth hormone. Because it acts upstream on the pituitary rather than supplying exogenous GH, its effect is gated by an intact pituitary and remains subject to normal physiological brakes, most importantly negative feedback from somatostatin and from GH/IGF-1. Downstream, any GH released drives hepatic production of insulin-like growth factor 1 (IGF-1). This "releaser" mechanism is the basis for the long-standing claim that sermorelin produces a more physiologic, pulsatile GH profile than direct recombinant GH injection, though that pharmacodynamic difference has not been shown to translate into superior clinical outcomes.
Mechanism pathways
Stimulating the pituitary's GHRH receptor to release the body's own growth hormone.
Growth-hormone-releasing hormone is made in the arcuate nucleus of the hypothalamus and travels through the hypophyseal portal circulation to the anterior pituitary, where it binds a class B G-protein-coupled receptor on somatotroph cells. Receptor activation raises intracellular cyclic AMP, which triggers both the synthesis of growth hormone and its release in pulses. Downstream, growth hormone acts on the liver and peripheral tissues to raise insulin-like growth factor 1, and IGF-1 in turn feeds back to restrain further growth hormone output. Somatostatin, released from a separate hypothalamic population, provides the opposing brake. The appeal of targeting this receptor rather than administering growth hormone directly is that the feedback architecture stays intact. Because release remains pulsatile and IGF-1 can still shut the system down, the pituitary sets a ceiling on how much growth hormone appears. Direct growth hormone administration bypasses that ceiling entirely. This is the central argument for the whole class, and it is a genuine pharmacological difference rather than a marketing distinction. All compounds in this group are analogs of the biologically active fragment of GHRH, which is the first twenty-nine amino acids. Native GHRH is cleaved almost immediately by dipeptidyl peptidase-4 at the amino terminus, so every analog is essentially a different answer to that vulnerability. Some substitute amino acids near the cleavage site. Some add a chemical group at the amino terminus that the enzyme cannot process. Some attach a linker that lets the molecule bind covalently to circulating albumin, stretching duration from minutes to days and turning discrete pulses into a sustained elevation, which is a meaningfully different physiological signal from a short pulse. One member of this group is an approved medicine for a specific indication, which means the receptor mechanism has been demonstrated in humans and not merely in animals. That approval does not extend to the rest of the group. Most of the compounds here have never been approved for any use anywhere, are sold as research chemicals of unverified identity and purity, and have human data limited to short studies showing that growth hormone rises after administration. Demonstrating that a hormone level moves is not the same as demonstrating that anything clinically meaningful follows from it, and for most of this class that second step has not been taken.
The evidence
The strongest human evidence is in pediatric diagnostics and idiopathic GH deficiency: sermorelin was studied and FDA-approved both as a provocative test of pituitary GH reserve and for treating growth failure in children with GHRH-responsive (hypothalamic) GH deficiency, where it can increase growth velocity (reviewed in BioDrugs 1999, PMID 18031173). Evidence for the popular adult "anti-aging," body-composition, sleep, and recovery claims is largely mechanistic or extrapolated rather than demonstrated; a frequently cited Clinical Interventions in Aging review (PMID 18046908) frames sermorelin in adult GH insufficiency as a rational but largely hypothetical approach, not an outcome-proven therapy. Notably, the well-known randomized controlled trial showing cognitive benefit from a GHRH analog in older adults and mild cognitive impairment (Baker et al., Archives of Neurology 2012, PMID 22869065) used tesamorelin, a different stabilized GHRH(1-44) analog, not sermorelin, so it should not be cited as direct sermorelin evidence. Overall, robust randomized trials of sermorelin for adult quality-of-life, longevity, or athletic outcomes are essentially absent.
The evidence, in brief
A GHRH(1-29) analogue that stimulates endogenous GH release. It was FDA-approved (brand Geref) for growth-hormone-deficiency use in children, but the manufacturer voluntarily withdrew it from the US market in 2008 for commercial reasons, so no active FDA label governs current use, which is mainly compounded and off-label.
Evidence maturity
An evidence-only reading: approval status, human vs preclinical data, mechanism and safety. Popularity never raises it. Research file #058
Some human signal atop preclinical work; gaps remain.
Some early human evidence exists but isn't definitive.
Claim receipts
Popular claims about Sermorelin, checked against the state of the evidence. The verdict describes evidence maturity, never an invented study result.
Approval covered pediatric GH-deficiency treatment and pituitary diagnostic testing, not adult wellness use.
Adult longevity and quality-of-life claims are framed in the literature as rational but untested.
Robust randomized trials for these adult outcomes are essentially absent.
The frequently cited cognition trial used tesamorelin, a different GHRH analog, not sermorelin.
Branded sermorelin was withdrawn from the US market in 2008; only compounded preparations remain.
Safety profile
In its approved pediatric and diagnostic use, sermorelin was generally well tolerated, with the most common reactions being transient injection-site reactions (redness, swelling, pain) and, less often, flushing, headache, dizziness, or transient warmth; uncommon hypersensitivity reactions were reported. Because it raises GH and IGF-1, the theoretical class concerns that apply to GH-axis stimulation are relevant, including fluid retention, joint or muscle discomfort, insulin resistance/glucose changes, and the general caution around GH-axis stimulation in people with active malignancy. Most safety data come from short-term, monitored, mostly pediatric settings; long-term safety of chronic adult use, especially via compounded products sold for off-label "wellness" purposes, has not been established, and compounded preparations carry additional uncertainty around purity, sterility, and dose accuracy. No doses or regimens are provided here.
Compound notes
- Sermorelin is a GHRH analog (the GRF 1-29 fragment) that stimulates the pituitary to release growth hormone.
- It is short-acting, producing a pulsatile GH release rather than a sustained elevation.
- It previously held FDA approval (brand Geref) for a diagnostic/pediatric GH-deficiency use; that product was withdrawn from the US market for commercial reasons, not safety reasons.
- No longer marketed as an FDA-approved product; current use is via compounding and research contexts.
- Long-term human safety for the popular off-label uses is not established.
Regulatory status
Sermorelin acetate was FDA-approved (brand Geref / Geref Diagnostic) for diagnostic testing of pituitary GH reserve and for idiopathic GH deficiency in children, but the branded products were voluntarily withdrawn from the US market in 2008 for commercial reasons (not for safety or efficacy failures); it is currently available in the US only as a compounded preparation, with no FDA-approved finished-drug product on the market.
Sold research-use-only; human evidence is limited or preclinical.
By the numbers
- 01Synthetic GHRH(1-29) analog, the shortest GHRH fragment with full receptor activity; it releases endogenous GH rather than being GH
- 02Acts on the pituitary GHRH receptor, so its effect depends on an intact pituitary and remains under normal somatostatin/IGF-1 feedback
- 03Marketed as Geref/Geref Diagnostic; FDA-approved uses were pediatric GH-deficiency diagnosis and treatment, not adult anti-aging
- 04Branded sermorelin was voluntarily withdrawn from the US market in 2008 for commercial reasons; only compounded product remains
- 05The widely cited GHRH-and-cognition RCT in older adults (Baker 2012) used tesamorelin, not sermorelin
- 06Robust randomized human trials for adult body-composition, longevity, sleep, or performance claims are lacking
Sermorelin: research formats
Choose the format you are researching to see route-specific notes.
Short-acting GHRH analog; administered before sleep to mimic the natural nocturnal GH pulse.
Sermorelin is typically sold as a 3 mg or 6 mg lyophilized vial. Reconstituting 3 mg with 3.0 mL BAC water gives 1,000 mcg/mL. Research protocols commonly target pre-sleep administration to coincide with the body's natural nocturnal GH peak.
Sources
Every factual claim above resolves to a real, published source.
- Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiencyBioDrugs, 1999, PMID 18031173
- Sermorelin: a better approach to management of adult-onset growth hormone insufficiency?Clinical Interventions in Aging, 2006, PMID 18046908
- Effects of growth hormone-releasing hormone on cognitive function in adults with mild cognitive impairment and healthy older adults: results of a controlled trial (used tesamorelin, a related GHRH analog, not sermorelin)Archives of Neurology, 2012, PMID 22869065
- Sermorelin (GHRH analog): PubMed search of the primary literaturePubMed search, NCBI
Cite this page
PepCue. “Sermorelin: the evidence.” PepCue, reviewed June 1, 2026. https://www.pepcue.app/p/sermorelin.
Log your doses, run the vial math, and keep a provider-ready record in PepCue.